Antiretroviral drugs

PreclinicalSmall molecule

NNational Institute of Allergy and Infectious Diseases (NIAID)

Antiretroviral drugs is one of 53 small molecule programs targeting Chronic Hepatitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisActive, not recruiting

MedicationWithdrawn

Chronic HepatitisPreclinical

Active, not recruiting

MedicationPreclinical

Withdrawn

Competition

Competitive Landscape

71 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

Baraclude

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

80 2

Viread

Gilead

Approved

8 3

PEG-Intron

Merck & Co.

Phase 3

43 4

Glucophage

EMD Serono

Approved

1 5

PEGASYS

Ppharmaand GmbH

Approved

24 6

Opdivo

Bristol-Myers Squibb

Phase 2

2 7

Pegylated Interferon Alfa

Merck & Co.

Phase 3

4 8

NA Therapy

GSK

Phase 3

2 9

AHB-137

AAusper Biopharma Co., Ltd.

Phase 3

3 10

Hydronidone

BBeijing Continent Pharmaceutical Co, Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Completed·VValme University Hospital··NCT01908660·192 enrolled

Histone Deacetylase Inhibitor1 trial

Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT03382834·31 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Antiretroviral drugs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antiretroviral drugs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antiretroviral drugs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

Antiretroviral drugs

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Quality of Life1 trial

Medication1 trial

Chronic Hepatitis1 trial

Histone Deacetylase Inhibitor1 trial

References

Drug Info

Quick Facts

Related News